Tolterodine Tartrate Extended Release

Warning

Tolterodine Tartrate is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma

Contraindications

• Urinary retention
• Gastric retention
• Uncontrolled narrow-angle glaucoma
• Known hypersensitivity to the drug or its ingredients

Adverse Reactions

• Dry mouth
• Headache
• Constipation
• Abdominal pain

General Guidance

Dose reduction to 2 mg daily may be necessary in patients with mild to moderate hepatic impairment, severe renal impairment, or those taking potent CYP3A4 inhibitors

Pregnancy

• No available data on use in pregnant women
• Animal studies showed no adverse effects at doses up to 9-12 times the clinical exposure

Nursing Mothers

• No information on presence in human milk
• Caution advised due to potential for adverse effects in the breastfed infant

Pediatric Use

• Not recommended for use in pediatric patients
• Efficacy not established in clinical studies

Geriatric Use

• No overall differences in safety observed between older and younger patients
• Dose adjustment not recommended based on age alone